{
    "root": "709e3342-23d5-10cd-3241-5ef6fdf924fe",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Lenalidomide",
    "value": "20250303",
    "ingredients": [
        {
            "name": "LENALIDOMIDE",
            "code": "F0P408N6V4"
        },
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "lenalidomide thalidomide analogue indicated treatment adult patients : multiple myeloma ( mm ) , combination dexamethasone ( 1.1 ) . mm , maintenance following autologous hematopoietic stem cell transplantation ( auto-hsct ) ( 1.1 ) . transfusion-dependent anemia due low- intermediate-1-risk myelodysplastic syndromes ( mds ) associated deletion 5q abnormality without additional cytogenetic abnormalities ( 1.2 ) . mantle cell lymphoma ( mcl ) whose disease relapsed progressed two prior therapies , one included bortezomib ( 1.3 ) . previously treated follicular lymphoma ( fl ) , combination rituximab product ( 1.4 ) . previously treated marginal zone lymphoma ( mzl ) , combination rituximab product ( 1.5 ) . limitations : lenalidomide indicated recommended treatment patients chronic lymphocytic leukemia ( cll ) outside controlled trials ( 1.4 ) .",
    "contraindications": "mm combination therapy : 25 mg daily orally days 1 21 repeated 28-day cycles . ( 2.1 ) . mm maintenance therapy following auto-hsct : 10 mg daily continuously days 1 28 repeated 28-day cycles ( 2.1 ) . mds : 10 mg daily ( 2.2 ) . mcl : 25 mg daily orally days 1 21 repeated 28-day cycles ( 2.3 ) . fl mzl : 20 mg daily orally days 1 21 repeated 28-day cycles 12 cycles ( 2.4 ) . renal impairment : adjust starting dose based creatinine clearance value ( 2.6 ) . concomitant therapy doses , full prescribing information ( 2.1 , 2.4 , 14.1 , 14.4 ) .",
    "warningsAndPrecautions": null,
    "adverseReactions": "pregnancy ( boxed warning , 4.1 , 5.1 , 8.1 ) . demonstrated severe hypersensitivity lenalidomide ( 4.2 , 5.9 , 5.15 ) .",
    "indications_original": "Lenalidomide is a thalidomide analogue indicated for the treatment of adult patients with: Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ). Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ). Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 ). Limitations of Use : Lenalidomide is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials ( 1.4 ).",
    "contraindications_original": "MM combination therapy: 25 mg once daily orally on Days 1 to 21 of repeated 28-day cycles. ( 2.1 ). MM maintenance therapy following auto-HSCT: 10 mg once daily continuously on Days 1 to 28 of repeated 28-day cycles ( 2.1 ). MDS: 10 mg once daily ( 2.2 ). MCL: 25 mg once daily orally on Days 1 to 21 of repeated 28-day cycles ( 2.3 ). FL or MZL: 20 mg once daily orally on Days 1 to 21 of repeated 28-day cycles for up to 12 cycles ( 2.4 ). Renal impairment: Adjust starting dose based on the creatinine clearance value ( 2.6 ). For concomitant therapy doses, see Full Prescribing Information ( 2.1 , 2.4 , 14.1 , 14.4 ).",
    "adverseReactions_original": "Pregnancy ( Boxed Warning , 4.1 , 5.1 , 8.1 ). Demonstrated severe hypersensitivity to lenalidomide ( 4.2 , 5.9 , 5.15 )."
}